Preliminary study on efficacy and safety of fluzoparib in patients with metastatic castration-resistant prostate cancer
Background and purpose: Inhibitors of poly (ADP-ribose) polymerase (PARPi) has been shown in multiple clinical trials to benefit survival in patients with homologous recombination repair (HRR) gene mutations in metastatic castration-resistant prostate cancer (mCRPC). Fluzoparib has been approved for...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Editorial Office of China Oncology
2021-08-01
|
| Colección: | Zhongguo aizheng zazhi |
| Materias: | |
| Acceso en línea: | http://www.china-oncology.com/thesisDetails#10.19401/j.cnki.1007-3639.2021.07.001 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|